Literature DB >> 3460996

The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism.

C Monder, C H Shackleton, H L Bradlow, M I New, E Stoner, F Iohan, V Lakshmi.   

Abstract

We describe the metabolism of cortisol (F) in three children, two of them siblings, with apparent mineralocorticoid excess (AME). As with prior patients with AME, oxidation of F to cortisone (E) was impaired, but reduction of E to F was not. We propose that this metabolic defect is caused by deficient 11-dehydrogenase associated with unimpaired 11-reductase. The following supporting observations were made: urinary C21 11-hydroxy metabolites exceeded C21 11-oxo metabolites: ratio of urinary cortols to cortolones, 6.6 +/- 2.8 (+/- SD; normal, 0.47); tetrahydrocortisol (THF) and alloTHF to tetrahydrocortisone, 14.6 +/- 5.6 (normal, approximately 1); normal subjects oxidized [11 alpha-3H]F with transfer of 3H to water; the patients did not; 11-hydroxy, but not 11-oxo, C19 steroids were excreted into the urine; and fibroblasts from patients had 5 times more 11-reductase activity than normal subjects, though fibroblasts from neither group had 11-dehydrogenase activity. Other defects of cortisol metabolism not directly associated with 11-dehydrogenase deficiency were found: impaired conversion of tetrahydro to hexahydro neutral steroids, indicating defective reductive metabolism of the side chain; depressed F production rate and increased half-life of circulating F, resulting in normal blood levels of F; increased excretion of unconjugated F metabolites; and decreased excretion of THF relative to alloTHF, consistent with a 5 beta-reductase defect. Excretion of acidic metabolites of F (cortoic acids) was within the normal range. However, little or no 20 beta-hydroxy acids were excreted, while the level of urinary 20 alpha-hydroxy acids was increased. The 11-hydroxy to 11-oxo ratio of acid metabolites was similar to values in normal subjects. The proportion of cortoic acids relative to neutral hexahydro metabolites was increased (0.37 to 1.27 in patients; 22 in normal subjects). We conclude that children with AME have multiple defects in the conversion of F to neutral metabolites, while metabolism to cortoic acids was less extensively affected. How the defects in cortisol metabolism and the symptoms of AME are related remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460996     DOI: 10.1210/jcem-63-3-550

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Further studies on the mechanism of the mineralocorticoid action of licorice in humans.

Authors:  D Armanini; S Lewicka; C Pratesi; M Scali; M C Zennaro; S Zovato; C Gottardo; M Simoncini; A Spigariol; V Zampollo
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

4.  Distribution of 11 beta-hydroxysteroid dehydrogenase along the rabbit nephron.

Authors:  J P Bonvalet; I Doignon; M Blot-Chabaud; P Pradelles; N Farman
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: overt and subclinical hypothyroidism.

Authors:  M C Vantyghem; A Ghulam; C Hober; C Schoonberg; M D'Herbomez; A Racadot; A Boersma; J Lefebvre
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

Review 7.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

9.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 10.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.